Diss. (sammanfattning) Stockholm : Karol. inst., 2005. / Härtill 5 uppsatser.

Diss. (sammanfattning) Umeå : Umeå universitet, 2006. / Härtill 4 uppsatser.

Thesis (Ph.D. in Neuroscience) -- University of Colorado Denver, 2008. / Typescript. Includes bibliographical references (leaves 110-125). Online version available via ProQuest Digital Dissertations.

Dissertation (Ph.D.)--University of South Florida, 2007. / Includes vita. Includes bibliographical references (leaves 109-141). Also available online.

Submitted by Carlos Alberto Arcaro Filho (carlos_arcaro@hotmail.com) on 2018-07-13T23:08:25Z No. of bitstreams: 1 Tese Final - Carlos Alberto Arcaro Filho.pdf: 7378512 bytes, checksum: cb295c066a7be41be3508e2daf64d24f (MD5) / Approved for entry into archive by Maria Irani Coito null (irani@fcfar.unesp.br) on 2018-07-16T13:17:13Z (GMT) No. of bitstreams: 1 arcarofilho_ca_dr_arafcf_int.pdf: 7378512 bytes, checksum: cb295c066a7be41be3508e2daf64d24f (MD5) / Made available in DSpace on 2018-07-16T13:17:14Z (GMT). No. of bitstreams: 1 arcarofilho_ca_dr_arafcf_int.pdf: 7378512 bytes, checksum: cb295c066a7be41be3508e2daf64d24f (MD5) Previous issue date: 2018-04-27 / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Considerando os avanços no conhecimento acerca dos mecanismos que controlam o metabolismo de proteínas na musculatura esquelética que permitiram a busca por novas opções para o tratamento das atrofias musculares, o presente estudo teve como objetivo a compreensão do potencial antiproteolítico de inibidores de fosfodiesterase, PDE (pentoxifilina, inibidor não-seletivo de PDE; rolipram, inibidor seletivo de PDE4) em músculos esqueléticos de ratos submetidos à atrofia muscular devido à insuficiência insulínica (diabetes mellitus experimental), com ênfase na elucidação da participação de componentes da sinalização do AMP cíclico (AMPc) nesta resposta. Ratos normais e diabéticos (60 mg/kg de estreptozotocina, administração intravenosa) foram tratados com salina (NS e DS) ou com 2 mg/kg de rolipram (NROL e DROL), ou com 25 mg/kg de pentoxifilina (NPTX e DPTX) durante 3 dias, por via intraperitoneal. Após três dias de tratamento, músculos soleus e extensor digitorum longus (EDL) foram removidos, pesados, congelados e processados para diversas análises: (i) conteúdo de AMPc (ensaio imunoenzimático); (ii) atividades das proteases proteassoma, calpaínas e caspase-3 (uso de substratos específicos fluorigênicos); (iii) níveis proteicos e/ou níveis de fosforilação de componentes das vias proteolíticas, efetores intracelulares sinalizatórios e fatores de transcrição (Western blotting); (iv) determinação dos níveis séricos de insulina e citocinas pró-inflamatórias. Foram realizados experimentos ex-vivo, para verificar a ação direta dos fármacos no controle da proteólise muscular e ativação de efetores intracelulares, via incubações dos músculos na presença de rolipram ou de agonistas de EPAC (Exchange protein directly activated by cAMP) e de PKA (proteína quinase dependente de AMPc), proteínas efetoras ativadas pelo AMPc. Também foram realizados experimentos no Laboratório do Prof. Dr. Marco Sandri, no Venetian Institute of Molecular Medicine, Padova, Itália, para a avaliação do papel de PDE4D no controle do processo autofágico-lisossomal em músculos esqueléticos de camundongos jejuados. Os tratamentos de animais diabéticos com rolipram (DROL) ou com pentoxifilina (DPTX) promoveram uma redução nas atividades do proteassoma e calpaínas em soleus e EDL, bem como nos níveis de componentes-chave do sistema proteolítico ubiquitina-proteassoma (MuRF-1, atrogin-1, conjugados poliubiquitinados), e aumento nos níveis de calpastatina (inibidor das calpaínas). Interesante ressaltar que o grupo DROL apresentou redução na atividade e níveis proteicos de caspase-3, em ambos os músculos, enquanto que o grupo DPTX apenas em músculos EDL. Contribuindo com a redução observada na atividade de caspase-3, houve uma redução nos níveis de Bax (proteína pró-apoptótica) e aumento nos níveis de Bcl-2 (proteína anti-apoptótica) em ambos os músculos de animais DROL. Animais diabéticos tratados com salina (DS) apresentaram aumento nas atividades das três proteases, bem como nos níveis de componentes participantes destes processos proteolíticos. Animais normais e diabéticos tratados com salina (NS e DS) apresentaram níveis de AMPc basais e semelhantes entre si, tanto em soleus quanto em EDL, enquanto que os tratamentos de ratos normais e diabéticos com pentoxifilina (NPTX e DPTX) ou rolipram (NROL e DROL) promoveram aumentos de AMPc, em ambos os músculos. Um dos mecanismos que podem estar envolvidos na inibição da proteólise muscular após aumentos nas concentrações de AMPc envolve a proteína EPAC, responsável por integrar a sinalização do AMPc e a sinalização insulínica via ativação da quinase AKT. Animais diabéticos tratados com pentoxifilina ou com rolipram apresentaram aumento nos níveis proteicos de EPAC 1 e na fosforilação de AKT, quando comparados ao grupo DS. Observamos também um aumento na fosforilação inibitória de fatores de transcrição FoxO 1 e 3a em ambos os músculos de animais DROL. Podemos sugerir que parte das ações de rolipram que culminaram em ativação de AKT e inibição de FoxO na musculatura esquelética possam estar associadas aos aumentos observados nos níveis circulantes de insulina em animais DROL. Investigamos, apenas nos animais tratados com rolipram, a possibilidade de participação da proteína PKA no controle da proteólise muscular. Em animais DROL houve ativação da PKA, verificada tanto pelo aumento na fosforilação de substratos de PKA, bem como do fator de transcrição CREB, em soleus e EDL. Vale destacar que animais DS apresentaram níveis reduzidos de p-CREB e de substratos fosforilados por PKA em soleus e EDL. Animais diabéticos tratados com os inibidores de PDE apresentaram uma diminuição de citocinas pró-inflamatórias séricas (TNF-, PTX e ROL; IL-1, ROL) e aumento nos níveis de insulina sérica (ROL) em relação aos animais DS. Nos estudos ex vivo, as incubações de músculos soleus e EDL com rolipram levaram a uma redução da proteólise total, bem como aumento na fosforilação de substratos de PKA e de AKT. Músculos soleus e EDL incubados com agonistas de EPAC apresentaram aumento na fosforilação de AKT, enquanto que a incubação com agonista de PKA promoveu aumento na fosforilação dos substratos de PKA (em ambos os músculos) e aumento na fosforilação de AKT (apenas em EDL), quando comparados aos músculos incubados na ausência do fármaco. Nos estudos para compreensão do papel de PDE4D no controle do processo autofágico-lisossomal, observou-se que o silenciamento gênico da PDE4D em músculos tibialis anterior promoveu uma preservação da massa muscular e da área da fibra em animais jejuados, quando comparados ao músculo controle. Músculos flexor digitorium brevis, silenciados para PDE4D, apresentaram diminuição na expressão de proteínas-chave do processo autofágico-lisossomal, tais como LC3 e p62. Estes resultados evidenciam os mecanismos que podem estar envolvidos na ação direta de inibidores de PDE no controle do metabolismo proteico muscular esquelético, via ativação de duas vias dependentes de AMPc: (i) a via PKA/CREB, que pode participar do controle da transcrição de Bcl-2 e calpastatina, bem como na inativação direta de caspases, inibindo assim os processos proteolíticos dependentes de caspase-3 e calpaínas, (ii) a via EPAC/AKT, via fosforilação e inibição de FoxO 1 e 3A, regulando a expressão dos atrogenes (MuRF-1 e atrogin-1) e promovendo uma diminuição na atividade do sistema ubiquitina-proteassoma. Além disso, o tratamento com inibidores de PDE diminuem o processo inflamatório e aumentam os níveis circulantes de insulina, ações que podem contribuir para os efeitos antiproteolíticos. Evidências iniciais também sugerem que PDE4D participa no controle do sistema autofágico-lisossomal na musculatura esquelética. Todos estes resultados indicam que PDE participam no controle de processos proteolíticos, portanto inibidores de PDE emergem como uma opção interessante na ativação da sinalização do AMPc na musculatura esquelética, com vistas à utilização futura no tratamento de quadros de perda de massa muscular durante situações de atrofia. / Considering the advances in the knowledge of the mechanisms controlling the protein metabolism in skeletal muscles that allowed the discover of new options for the treatment of muscle atrophies, the present study aimed to understand the antiproteolytic potential of phosphodiesterase (PDE) inhibitors (pentoxifylline, a non-selective PDE inhibitor; rolipram, a selective PDE 4 inhibitor), in skeletal muscles of rats submitted to muscle atrophy due to insulin insufficiency (experimental diabetes mellitus), with emphasis on the elucidation of the participation of cyclic AMP (cAMP) signaling components. Normal and diabetic rats (60 mg/kg streptozotocin, intravenous administration) were treated intraperitoneally with saline (NS and DS) or with 2 mg/kg rolipram (NROL and DROL) or with 25 mg/kg pentoxifylline (NPTX and DPTX) for 3 days. After three days of treatments, soleus and extensor digitorum longus (EDL) muscles were removed, weighed, frozen and processed for several analyzes: (i) cAMP content; (ii) activities of proteasome, calpain and caspase-3 (use of specific fluorigenic substrates); (iii) protein levels and/or phosphorylation levels of components of proteolytic pathways, intracellular signaling effectors and transcription factors (Western blotting); (iv) determination of serum insulin and proinflammatory cytokines levels. Ex vivo experiments were performed to verify the direct action of the drugs in the control of muscle proteolysis and activation of intracellular effectors, via muscle incubations in the presence of rolipram or agonists of EPAC (Exchange protein directly activated by cAMP) and PKA (cAMP-dependent protein kinase), intracellular effectors activated by cAMP. Experiments were also carried out in the Laboratory of Prof. Dr. Marco Sandri at the Venetian Institute of Molecular Medicine, Padova, Italy, for the evaluation of the role of PDE4D in controlling the autophagic-lysosomal process in skeletal muscles of starved mice. Treatments of diabetic animals with rolipram (DROL) or pentoxifylline (DPTX) promoted a reduction in the activities of proteasome and calpain in soleus and EDL, as well as reduced the levels of key components of the ubiquitin-proteasome system (MuRF-1, atrogin-1, polyubiquitinated conjugates), and increased the levels of calpastatin (calpain inhibitor). Interestingly, DROL rats showed a reduction in the activity and in the protein levels of caspase-3 in both muscles, whereas DPTX rat had reductions only in EDL muscles. Contributing to the reduction in caspase-3 activity, it was observed a reduction in the content of Bax (pro-apoptotic protein) and an increase of Bcl-2 (anti-apoptotic protein) in both muscles of DROL rats. Diabetic animals treated with saline (DS) showed an increase in the activities of the three proteases, as well as increases in the levels of components belonging to these proteolytic processes. Normal and diabetic animals treated with saline (NS and DS) had basal and similar levels of cAMP in both soleus and EDL, whereas the treatments of normal and diabetic rats with pentoxifylline (NPTX and DPTX) or with rolipram (NROL and DROL) promoted increases in cAMP in both muscles. One of the mechanisms that may be involved in the muscle proteolysis inhibition after increases in cAMP involves the EPAC protein, responsible for integrating the cAMP and the insulin signaling pathways via AKT activation. Diabetic animals treated with pentoxifylline or with rolipram showed an increase in the protein levels of EPAC 1 and in the phosphorylation of AKT, when compared with the DS group. We also observed an increase in the phosphorylation (inhibitory) of FoxO 1 and 3a in both muscles of DROL rats. It can be suggested that part of the rolipram actions causing AKT activation and FoxO inhibition in skeletal muscles may be associated with the increases in the circulating levels of insulin observed in DROL animals. It was investigated, only in animals treated with rolipram, the possible involvement of PKA in the control of muscle proteolysis. DROL rats had activation of PKA, verified both by the increase in the phosphorylation of PKA substrates, as well as in the phophorylation of the transcription factor CREB, in soleus and EDL. DS rats had decreased levels of p-CREB and of the PKA substrates, in soleus and EDL. Diabetic animals treated with PDE inhibitors showed a decrease in serum proinflammatory cytokines (TNF-, PTX and ROL; IL-1, ROL) when compared with DS. In ex vivo studies, incubations of soleus and EDL with rolipram caused a reduction of the total proteolysis as well as an increase in the phosphorylation of PKA substrates and and of AKT. Soleus and EDL muscles incubated with EPAC agonist showed increased in the AKT phosphorylation, whereas incubation with PKA agonist promoted an increase in the phosphorylation of PKA substrates (in both muscles) and and increase in the AKT phosphorylation (EDL), when compared with muscles incubated in the absence of the drugs. In studies to understand the role of PDE4D in the control of the autophagic-lysosomal process, it was observed that the PDE4D gene silencing in anterior tibialis muscles caused a preservation of the muscle mass and fiber area in fasted animals when compared with control muscle. Flexor digitorium brevis muscles, silenced for PDE4D, showed a decreased expression of key proteins of the autophagic-lysosomal process, such as LC3 and p62. These results suggested the mechanisms that may be involved in the direct action of PDE inhibitors in the control of skeletal muscle protein metabolism, through activation of two cAMP-dependent pathways: (i) the PKA/CREB pathway, which may participate in transcriptional control of Bcl-2 and calpastatin, as well as causing direct inactivation of caspases, thus inhibiting the proteolytic processes dependent on caspase-3 and calpains, (ii) the EPAC/AKT pathway, via phosphorylation and inhibition of FoxO 1 and 3a factors, regulating the expression of atrogenes (MuRF-1 and atrogin-1) and promoting a decrease in activity of ubiquitin-proteasome system. Treatments with PDE inhibitors also decreased the inflammatory process and increased the circulating linsulin levels, which may be contributing to the antiproteolytic responses. Initial evidence also suggests that PDE4D participates in the control of the autophagy-lysosomal system in skeletal muscles. All these results indicate that PDE participate in the control of proteolytic processes, therefore PDE inhibitors emerge as an interesting option to activate the cAMP signaling in the skeletal muscles, which may be used in the future in treatments muscle mass loss during atrophy situations. / FAPESP: Processo 2013/18861-2 / FAPESP: Processo 2014/12202-0 / FAPESP: Processo 2017/02348-5

Mycobacterium tuberculosis is one of the most successful human pathogens, estimated to have infected close to one-third of the global human population. In order to survive within its host, M. tuberculosis utilises multiple signalling strategies, one of them being synthesis and secretion of universal second messenger cAMP. This process is enabled by the presence of sixteen predicted adenylyl cyclases in the genome of M. tuberculosis H37Rv, ten of which have been characterised in vitro. The synthesized cAMP is recognised by ten putative cAMP-binding proteins in which the cyclic AMP-binding domain is associated with a variety of enzymatic domains. The cAMP signal can be extinguished by degradation by phosphodiesterase’s, secretion into the extracellular milieu or via sequestration of the nucleotide by upregulation of a high-affinity cAMP-binding protein. Of the sixteen adenylyl cyclases (ACs) encoded by M. tuberculosis H37Rv, a subset of multidomain adenylyl cyclases remain poorly characterised, primarily due to challenges associated with studying these in vitro. The adenylyl cyclase domain in these proteins is associated with an NB-ARC domain (nucleotide binding domain common to APAF-1, plant R proteins and CED-4), a TPR domain (tetratricopeptide repeat) and an LuxR-type HTH motif (helix-turn-helix). This architecture places these multidomain mycobacterial ACs within a larger group of STAND (Signal transduction ATPase’s with numerous domains) proteins, and hence they will be referred to as STAND ACs. The STAND proteins are a recently recognised class of multidomain ATPases which integrate a variety of signals prior to activation. Activation is accompanied by formation of large oligomeric signalling hubs which facilitate downstream signalling events. While most STAND proteins have a single effector domain followed by an NB-ARC domain and a scaffolding domain, the STAND ACs distinguish themselves by retaining two effector domains, the AC domain and the HTH domain, at the N- and C- termini respectively. The cyclase, NB-ARC, TPR and HTH domains have widely divergent taxonomic distributions making the presence of these four domains in a single polypeptide rare. In fact, proteins with cyclase-NB-ARC-TPR-HTH (C-A-T-H) domain organisation were found to be encoded almost exclusively by slow growing mycobacterial species, a clade that harbours most mycobacterial pathogens, such as M. tuberculosis and M. leprae. Notably, one of the STAND ACs, Rv0386, is the only mycobacterial AC shown till date to be required for virulence of M. tuberculosis in mice. Using phylogenetic, the evolutionary underpinnings of this domain architecture were examined. The STAND ACs appear to have most likely evolved via a domain gain event from a cyclase-ATPase-TPR progenitor encoded by a strain ancestral to M. marina. Subsequently, the genes duplicated and diverged, sometimes leading to frameshift mutations splitting the cyclase domain from the C-terminal domains. Consequently, M. tuberculosis encodes for three ‘full-length’ STAND ACs, namely, Rv0386, Rv1358 and Rv2488c and one split STAND AC. The split STAND AC is made up of Rv0891c, containing the AC domain, and Rv0890c, containing the NB-ARC, TPR and HTH domains. rv0891c and rv0890c were found to be expressed as an operatic transcript, though they were translationally uncoupled. Pertinently, M. Canetti, an early-branching species of the M. tuberculosis complex, contains an orthologue of Rv0891c and Rv0890c where all four domains are present in a single polypeptide. Sequence analysis of the four STAND ACs in M. tuberculosis allowed predictions of significant divergence in function. These proteins showed high sequence conservation in their HTH domains, with substantial sequence divergence in their TPR, NB-ARC and AC domains. Biochemical analysis on the AC domains revealed that Rv0891c and Rv2488c possessed poor or no AC activity, respectively. On the other hand, the cyclase domain of Rv0386 could catalyse cAMP synthesis. Moreover, for both Rv0891c and Rv0386, presence of the C-terminal domains potentiated adenylyl cyclase activity, suggestive of allosteric regulation within the STAND AC module. Studies on Rv0891c also revealed that the protein could inhibit the adenylyl cyclase activity of Rv0386 in trans. This result thus provided a novel mechanism by which proteins harbouring poorly active/inactive adenylyl cyclase domains could contribute to cAMP levels, by acting as inhibitors of other adenylyl cyclases. The STAND ACs were found to be inactive ATPases. Additionally, incubation with nucleotides did not stimulate oligomerisation of these proteins, unlike what has been shown for several other STAND proteins. However, mutations in the NB-ARC domain perturbed the basal oligomeric state of these proteins, indicating that the NB-ARC domain can influence self- association. A subset of NB-ARC domain mutants also showed increased adenylyl cyclase activity, reiterating the inter-domain cross-talk in the STAND ACs. Since the AC activity of these proteins was meagre, the properties of the HTH domain were examined, as an alternative effector domain. Genomic SELEX was performed using the TPR-HTH domains of Rv0890c, and revealed a set of sequences that bound to this protein, though they lacked common sequence features. Further analysis revealed that Rv0890c bound to DNA in a sequence-independent manner, through the HTH domain. This binding was cooperative with multiple protein units engaging in DNA-binding. Due to the cooperative nature of binding and the lack of sequence preference, Rv0890c appeared coat the DNA molecule. This was further proved by the ability of Rv0890c to protect DNA from DNaseI-mediated degradation, and the requirement for long DNA sequences to form stable DNA-protein complexes. Studies also revealed that Rv0890c interacted with RNA and ssDNA. In fact, the protein as purified from heterologously expressing E. coli cells was bound to RNA. RNA-binding by a LuxR-type HTH has not been reported previously, providing a new function for this class of HTHs. Interestingly, nucleic acid-binding by a fusion Rv0891c-Rv0890c protein, similar to the one encoded in M. canetti, was shown to stimulate adenylyl cyclase activity. This was likely due to a relief of inhibitory interactions between the TPR-HTH and the AC domains, on DNA-binding. Given the high sequence similarity between the HTH domains of the STAND ACs, they were expected to bind to DNA in an identical manner. Indeed, the HTH domains of Rv0386 and Rv1358 engaged with DNA with an identical affinity as Rv0890c. Sequence comparisons in the HTH domain enabled identification of conserved basic residues, of which one, R850 was essential for nucleic acid-binding. Surprisingly however, Rv0386 and Rv1358 did not exhibit RNA-binding, pointing towards functional divergence of Rv0890c from its paralogues. Since the HTH domains of the STAND ACs were highly conserved, it was possible that the ability to bind to RNA was instead dictated by the adjacent TPR modules. To examine this possibility, TPR domains were swapped between Rv0890c and Rv0386. Interestingly, both the chimeric proteins showed a reduced ability to bind to DNA, while showing a complete absence of RNA- binding. These results suggested that the TPR domains were critical in modulating nucleic acid-binding. Moreover, the effect of the TPR domain was context-dependent, since the presence of non-cognate TPR domains hampered nucleic acid-binding. However, the ability to bind to RNA was not solely governed by the TPR domain since the Rv0890cTPR-Rv0386HTH chimeric protein did not show RNA-binding, in spite of containing a permissive TPR domain. To further dissect the molecular requirements for RNA-binding, the conservation of basic residues between the HTH domains of Rv0890c versus Rv1358 and Rv0386 was examined. Interestingly the HTH domain Rv0890c contained two additional positively charged residues over Rv1358 and Rv0386. Mutations of these abolished RNA-binding by Rv0890c. Thus the evolution of two basic residues permit Rv0890c to diverge in its nucleic acid-binding properties, a possible example of defunctionalisation following gene duplication. In summary, this thesis attempts to understand the evolution and functions of the STAND ACs, a group of pathogenically relevant and uniquely mycobacterial multidomain proteins. Phylogenetic analysis revealed an expansion of this gene family in slow growing mycobacteria. Biochemical characterisation showed that following gene duplication, the resulting proteins diverge both in their ability to synthesize cAMP and in their association with nucleic acids. Studies on these proteins also revealed novel mechanisms of regulation of mycobacterial cAMP levels. Additionally, these proteins exhibited indiscriminate binding to DNA/nucleic acids indicating that they may be responsible for global functions in the cell which extend beyond cAMP synthesis.

The effects of parathyroid hormone (PTH), prostaglandins (PGE1, PGE2, PGF2a), cAMP, cAMP-analogues, phosphodiesterase (PDE) inhibitors and la (OH) D3 on bone resorption and associated cellular process have been studied in a bone organ culture system using half- calvaria from 6-7 day-old mice. Bone resorption was assessed by determining the release of calcium (Ca2+), inorganic phosphate (Pi) and 45Ca from the calvarial bones to the culture media. The release of lysosomal enzymes was studied by analysing the activities of β-glucuronidase, β-N-acetyl- glucosaminidase, β-galactosidase and p-nitrophenyl phosphatase in bone expiants and culture media. The release of non-lysosomal enzymes was followed by assaying the activities of lactate dehydrogenase (LDH), aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) in the expiants as well as the media. In addition glucose consumption and lactate production was registered. The findings may be summarized as follows: 1. cAMP and PDE-inhibitors have the capacity to inhibit the initial stages of spontaneous as well as PTH- PGE1- and PGE2-stimulated bone resorption. 2. cAMP and PDE-inhibitors produce after a lag period, or a period of reduced bone resorption, a stimulatory effect on bone resorption. 3. There is a significant correlation between bone resorption and lysosomal enzyme release both as regards the inhibitory and stimulatory effect of cAMP. 4. PGE2 and la (OH) D3 increase the release of lysosomal enzymes in parallel with bone resorption. 5. Bone resorption stimulated by cAMP and PGE2 is associated with increased glucose consumption and lactate production, while la (OH) D3 promotes bone resorption without any change with regard to these parameters of glucose metabolism. It is concluded that the initial stages of bone resorption stimulated by PTH, PGE1 and PGE2 is medited by cAMP-independent mechanisms, but that this nucleotide may be an intracellular mediator of these hormones of later stages of bone resorption. It is suggested that the role played by cAMP may be related to the capacity of PTH and PGE2 to develop new osteoclasts. The observations further support the concept that lysosomal enzyme release is intimately associated with bone resorption. Finally it is concluded that increased lactate production seems to be related to bone resorption stimulated by agents which increase the level of cAMP (PTH, PGE2, dbcAMP), but that it is not an indispensible part of the mechanism by which the osteoclasts solubilize bone mineral. / digitalisering@umu.se

The aim of the present investigation was to study the influence of the sympathetic nervous system and of various adrenoceptor agents on enzyme secretion and morphology in rat parotid and guinea-pig submandibular glands. Biochemical methods were combined with electron microscopical techniques. Two different in vitro systems were employed, batch-incubation and microperifusion, to characterize the sympathetically evoked amylase release and its correlation to cyclic AMP. By using various selective β-adrenoceptor agonists and antagonists a dominance of the β1-adrenoceptor over the β2 - in regulating amylase release - was establ ished. Continuous noradrenaline perifusion caused a rapid initial amylase discharge, closely correlated to tissue levels of cyclic AMP; no correlation between the two was observed during the later phase. Prenalterol (a β1-agonist) failed to elevate glandular cyclic AMP. This was in contrast to its potent secretagogic effect. On the other hand, terbutaline (a β2-agonist) was a weak secretagogue but markedly raised the levels of cyclic AMP. Thus, β-adrenoceptor activation may lead to release of large amounts of amylase despite minimal or no increase in cyclic AMP. Moreover, these effects seemed to be dissociated in salivary glands with regard to the β-adrenoceptor subtypes. This was further substantiated by the findings that repeated injections of prenalterol induced qualitative changes in the granule populations, similar to those caused by the non-selective β-agonist isoprenaline. Terbutaline was without effect. However, acinar cells size was increased following both prenalterol and terbutaline treatment. The data suggest that the 3-adrenergic effects on acinar cell size and granule population may be independently regulated. A decreased sympathetic activity of long duration was induced by neonatal or adult extirpation of the superior cervical ganlion on one side. Acinar cell size, as well as granule and amylase content was reduced 9 weeks after neonatal denervation. Ganglionectomy performed in adult animals was without significant effects. The secretory behaviour of neonatally denervated glands was characterized by an increased postjunctional sensitivity to 3-adrenoceptor agonists. Of special interest was the finding that neonatal denervation seemed to transform terbutaline from a partial to a full secretory agonist, thus changing its effects in the direction of those of prenalterol and noradrenaline. Moreover, increased levels of cyclic AMP as well as an enhanced response to DBcAMP were noted in the denervated glands as were intracellular changes. The denervation supersensitivity after neonatal denervation seems to differ from that observed in adult denervated glands. The results of the studies on denervated glands suggest that the sympathetic nervous system plays a fundamental role in the early maturation of the rat parotid gland as well as for the development of the β-adrenoceptor subtypes. / <p>S. 1-34: sammanfattning, s. 35-128: 6 uppsatser</p> / digitalisering@umu

The discovery of cyclic AMP (cAMP), nearly 50 years ago by Sutherland radically altered the appreciation of metabolic regulation. Since then the presence of cAMP and its tremendous physiological impact has been demonstrated in many prokaryotic systems. In fact, virulence mechanisms of several pathogens known today exploit cAMP dependent pathways. Interestingly the genome of Mycobacterium tuberculosis H37Rv, the causative agent of tuberculosis, encodes as many as 16 adenylyl cyclases (enzymes that convert ATP to 3’, 5’-cAMP) and 10 cyclic-nucleotide binding proteins. Recent reports show that bacterial-derived cAMP manipulates host signaling for bacterial survival, suggesting an important role for cAMP in the pathogenesis of M. tuberculosis. A large number of non-pathogenic species of mycobacteria also share and conserve several of these cAMP metabolism genes, suggesting that cAMP is not only important for pathogenesis but also may play a critical physiological role in the genus. The work carried out in this thesis aims at a better understanding of the role of cAMP by studying the adenylyl cyclases and cyclic AMP receptor proteins (CRPs) from Mycobacterium smegmatis, a non-pathogenic member of the genus. Intracellular cAMP levels in a cell are precisely maintained by modulating the activities of the adenylyl cyclases (cAMP synthesising enzymes), the phosphodiesterases (cAMP hydrolysing enzymes) and the secretion machinery, if any. To assess the role of cAMP in mycobacteria, cAMP levels were measured in M. smegmatis during growth and under various stress conditions. The results show that cAMP levels peak at log phase of growth and decline thereafter. Under acidic conditions or on perturbing the cell-wall, cellular cAMP levels are altered, which indicate a possible role of cAMP in stress adaptation. Earlier work in our laboratory has led to the identification of multiple adenylyl cyclases in the mycobacterial genomes. These cyclases are similar in sequence to the mammalian enzymes and several of them have been shown to be active in vitro displaying a diverse range of biochemical properties. The M. smegmatis genome encodes 10 adenylyl cyclase-like genes. In order to understand the role of cAMP in M. smegmatis, individual cyclases were analysed for their biochemical properties and physiological functions. The work presented in this thesis is concerned with the functional characterization of MSMEG_3578 and MSMEG_3780, two of the several adenylyl cyclases from M. smegmatis. MSMEG_3578 encodes for a protein that comprises two transmembrane domains, an extracellular receptor-like domain, a membrane anchoring HAMP domain and an intracellular cyclase domain. The cyclase domain is closely related to mammalian cyclases but lacks the canonical residues that are critical for the catalysis of class III cyclases. Interestingly, the stop codon of this gene overlaps with the start codon of the downstream gene, MSMEG_3579 (a putative cyclic nucleotide gated mechanosensitive ion channel), suggesting a functional link between the two genes. The conservation of this gene pair across the mycobacterial genus indicates the importance of this putative receptor-effector pair in the physiology of mycobacteria. Additionally, microarray analysis by various groups have shown that this gene pair in Mycobacterium tuberculosis is differentially regulated in conditions that mimic stress the bacteria may experience during infection. In order to ascertain the physiological role of MSMEG_3578, a knock-out M. smegmatis strain was generated and tested for growth and cAMP defects. The knock-out strain showed growth and cAMP profiles similar to the wild-type strain. Over-expression of MSMEG_3578 in M. smegmatis resulted in a significant rise in cAMP levels. Interestingly, over-expression of the MSMEG_3578 adenylyl cyclase in E. coli did not lead to an elevation in cAMP levels indicating that other mycobacterial proteins may be required for the activity of MSMEG_3578 in vivo. In agreement with this, the purified adenylyl cyclase domain of MSMEG_3578 was found to be biochemically inactive in vitro. Additionally, the over-expressing strain has altered colony morphology as compared to the wild type strain. Perturbation of cAMP levels by over-expression of other cyclases also leads to a similar colony morphology phenotype, indicating the phenotype to be controlled by cAMP in general rather than by a specific cyclase in the cell. MSMEG_3780 is a highly conserved, biochemically active adenylyl cyclase, speculated to play a house-keeping function in M. smegmatis. Its orthologs from M. tuberculosis (Rv1647) and M. leprae (ML1399) have been biochemically characterized earlier in our laboratory. To unravel the role of this gene in vivo, the ∆MSMEG_3780 strain was tested for growth and cAMP defects under various conditions. The deletion strain did not show any difference in growth rate or morphology when compared to the wild-type strain. However it showed a reduction in intracellular cAMP levels at the log-phase of growth. Reintroduction of the MSMEG_3780 gene in the deletion strain restored cAMP to wild-type levels, thus indicating a crucial role for this adenylyl cyclase in the maintenance of intracellular cAMP levels during logarithmic growth. In order to investigate the regulation of the MSMEG_3780 gene, its promoter activity was tested under various stress-conditions. Acid-stress specifically resulted in the repression of the MSMEG_3780 promoter activity, a condition which also leads to a decrease in cAMP levels in the cells. Further evidence for the susceptibility of the MSMEG_3780 gene to acid-stress was obtained when the ∆MSMEG_3780 strain failed to reduce intracellular cAMP content upon sustained acid-stress conditions. Since Rv1647 shares similar biochemical properties with MSMEG_3780 and can also heterodimerize with the MSMEG_3780 protein in vitro, it was interesting to test whether the M. tuberculosis ortholog could functionally complement MSMEG_3780. To assess this, a complement strain was generated that contained the Rv1647 gene under the control of MSMEG_3780 promoter, integrated into the genome of ∆MSMEG_3780 strain. Rv1647 protein was able to restore the cAMP phenotype seen on acid stress as well as the cAMP levels in the mutant strain at the log phase of growth. This study indicated the role of cAMP and MSMEG_3780 in acid adaptation and also suggested a non-redundancy of adenylyl cyclases in mycobacteria, where different individual cyclases may have unique functions in the cells. Since Rv1647 could complement the cAMP defective phenotype in ∆MSMEG_3780, this suggests functional parallels between the proteins from the two species. Bacterial adaptation to environmental stress is brought about by a rapid change in its gene expression profile. Cyclic AMP plays an important role by binding to and activating a transcriptional factor, cAMP receptor protein or CRP. We have identified two CRPs from M. smegmatis, viz., MSMEG_0539 and MSMEG_6189 that possess high similarity at the amino acid level (78% overall sequence identity). The CRP ortholog from M. tuberculosis, Rv3676 has been characterized structurally, biochemically and functionally earlier. Western blot and RT-PCR analyses showed that CRPs in M. smegmatis were present during all phases of growth. Both the CRPs were cloned, expressed and shown to bind cAMP. Since the DNA binding domains of Rv3676 and the two M. smegmatis CRPs are nearly identical, the CRPs from M. smegmatis were predicted to bind similar target sequences. Interestingly, a CRP site was identified in the promoter of the MSMEG_3780 gene, suggesting a possible feed-forward or feed-back loop, where the enzymatic product of the adenylyl cyclase now governs its own gene expression. We performed Electrophoretic Mobility Gel Shift Assays (EMSAs) with M. smegmatis lysates to show that CRP binds to the MSMEG_3780 promoter at the CRP site. Subsequent Chromatin Immunoprecipitation (ChIP) assays confirmed that CRP binding to the MSMEG_3780 promoter occurred in vivo. To investigate the role of CRP in the regulation of the MSMEG_3780 gene, luciferase reporter assays with the wild-type and CRP site mutant promoters were carried out. Results suggest that CRP regulates the MSMEG_3780 gene under osmotic stress. However, CRP did not play any role in basal expression of MSMEG_3780 during growth. To assess which CRP of the two is functionally linked to the MSMEG_3780 promoter, we carried out a footprint assay with purified CRPs. It was intriguing to note that both the CRPs were in fact able to bind the promoter albeit under different conditions. Whereas MSMEG_6189 bound the promoter both in the presence and absence of cAMP, MSMEG_0539 bound the promoter only in the presence of cAMP. MSMEG_6189 thus deviates from the accepted CRP paradigm that seeks an absolute requirement of cAMP for specific DNA binding. The present study identifies cAMP as an important stress signal in M. smegmatis. Using MSMEG_3780 as a model gene, the role of cAMP in mycobacteria was studied. The two divergent CRPs that were characterized may function and dictate cAMP-mediated and perhaps independent functions in cells. Taken together, our results provide compelling evidence for the important role of cAMP in the general physiology and stress adaptation in M. smegmatis.

Einleitung: / Introduction: